Journals A-Z
All Subjects
Free Journals
sciepub.com
International Journal of Clinical and Diagnostic Research
ISSN (Print): 2395-3403 ISSN (Online): 2395-3403 Website: https://www.sciepub.com/journal/ijcdr Editor-in-chief: Apply for this position
Open Access
Journal Browser
Go
Issue 4, Volume 6
Article Metrics
  • 5157
    Views
  • 3810
    Saves
  • 0
    Citations
  • 0
    Likes
Export Article
International Journal of Clinical and Diagnostic Research. 2018, 6(4), 88-94
DOI: 10.12691/ijcdr-6-4-1
Open AccessArticle

AN EMERGING CAUSE OF TREATABLE ENCEPHALITIS: A CASE OF ANTI-NMDA RECEPTOR (NMDAR) ENCEPHALITIS

Praveen Kumar Yadav1, and Dipanwita Sen2

1Department of Neuromedicine, The Mission Hospital, Durgapur, Paschim Burdwan, West Bengal, Pin-713212

2Department of Obstrectics and Gynecology, The Mission Hospital, Durgapur, Paschim Burdwan, West Bengal, Pin-713212

Pub. Date: August 13, 2018
Full Text PDF (397 KB)

Cite this paper:
Praveen Kumar Yadav and Dipanwita Sen. AN EMERGING CAUSE OF TREATABLE ENCEPHALITIS: A CASE OF ANTI-NMDA RECEPTOR (NMDAR) ENCEPHALITIS. International Journal of Clinical and Diagnostic Research. 2018; 6(4):88-94. doi: 10.12691/ijcdr-6-4-1

Abstract

Anti N-methyl-D-aspartate Receptor (NMDAR) encephalitis is the most common type of autoimmune limbic encephalitis known. It is characterized by Sub acute onset of psychiatric symptoms along with refractory epilepsy, orofacial and limb dyskinesias and dysautonomia. High clinical suspicion and appropriate antibody testing in CSF and serum is required for early diagnosis and initiation of Immunotherapy. Delay in treatment may lead to significant permanent neurodeficits as well as mortality. Here we present a case of 20 year old female who presented with hallmark clinical features and high titre NMDAR antibody positivity in serum and CSF. She failed to respond with first line Immunosuppressant (Combination of immunoglobulin and steroids) and had to be started on weekly Rituximab for a month with dramatic clinical response. She was continued on oral steroids for 6 months and Azathioprine for 1 year.USS Pelvis and MRI Pelvis did not reveal any ovarian teratoma even after two and half years of regular follow up with 6 monthly Ultrasound Scan of the pelvis.This case highlights that we should diagnose the illness early and initiate second line treatment like Rituximab in case of failure to respond to first line agents in 10 days.

Keywords:
NMDAR Encephalitis Rituximab Teratoma Seizures

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Manuscript template